About
Novartis is an innovative medicines company.Every day，we work to reimagine medicine to improve and extend people’s live s so that patients，healthcare professionals and societies are empowed in the face of serious disease.Our medicines reach more than250million people worldwide。
Patients and caregivers
Information for patients and their caregivers including clinical trial recruiting，managed access programs，funding opportunities for patient organizations and side effects reporting。
Healthcare professionals
资源for physicians and other healthcare professionals including clinical trial recruiting，grant funding，congresses and country-level information。
Research&development
Discover how Novartis turns breakthrough science into transformative，high-value treatments。
环境，自然和governance
Learn about our commitments to making a positive impact on the world by providing access to innovative medicines，protecting the environment，and upholding high ethical standards.Explore the Novartis in Society Integrated Report。
Investors
Updates and resources for investors including financial information，disclosures，events，share price，ESG and reporting。
新闻，新闻
Information for journalists including media releases，statements，stories，multimedia resources and more。
Careers
Novartis is hiring！Find open positions，learn more about our strategy and culture，and apply today。
主页
Working together，we can reimagine medicine to improve and extend people’s lives。
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition.Learn more about the active studies conducted by Novartis including opportunities to get involved。
Evaluate Long-term Safety，Tolerability and Efficacy of Iptacopan in Study Particcipants With aHUS
Study of Safety and of the Mechanism of BLZ945 in ALS Patients
AHUS，AHUS，AHUS，AHUS，AHUS，AHUS，Atpical Hemolytic Uremic Syndrome，Atpical Hemolytic Uremic Syndrome，Atpical Hemolytic Uremic Uremic Syndrome，AHUS
Study to Evaluate the Pharmacokinetics，Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
Long-term Follow-up（LTFU）of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells（HSPC）
A Study of Safety and Efficacy of KFA 115 Alone and in Combination With Pembrolizame in Patients With Select Advanced Cancers
六向Less Than12 Years With Asthma，Pharmacokinetics，Pharmacodynamics，Safety and Tolerability of Glycopyrronium（Bromide）in Children
Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy
Real-world Study to Assess Safety and Effectiveness of Xolair®in Pediatric Chronic Spontaneous Urticaria in China
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone